The Biden administration will move Tuesday to reclassify marijuana as a lower-risk substance, a person familiar with the plans told CNN. This decision marks a significant shift in federal policy on marijuana and could have far-reaching implications for the industry and patients who rely on the drug for medical purposes. The move comes as more states legalize marijuana for both medical and recreational use, prompting calls for federal reform.
The U.S. Drug Enforcement Administration is loosening federal restrictions on marijuana and concurring that the drug has medical value. This acknowledgment of marijuana's medical benefits could pave the way for more research into the drug's potential therapeutic uses and lead to the development of new treatments for a variety of conditions. The decision is a departure from the DEA's previous stance on marijuana, which classified it as a Schedule I controlled substance with no accepted medical use.
In a milestone move, the Drug Enforcement Administration is calling for cannabis to be reclassified under federal law, according to an AP report. The DEA's recommendation to reschedule marijuana could signal a shift in how the federal government views the drug and may open the door to broader legalization efforts. The move is seen as a step toward aligning federal and state laws on marijuana and addressing the disparities in how the drug is regulated.
The federal government's plan would recategorize pot, once deemed highly dangerous, addictive and without medical use, as a prescribable drug. This reclassification of marijuana could have significant implications for patients who rely on the drug for relief from a range of medical conditions. It could also create new opportunities for businesses in the cannabis industry and generate tax revenue for states that choose to legalize the drug.
For the first time, the Drug Enforcement Administration has called for 'botanical cannabis' to be reclassified under federal law. This decision could have implications for how marijuana is regulated and could pave the way for broader legalization efforts at the federal level. It could also lead to increased access to medical marijuana for patients who could benefit from its therapeutic properties.
Cannabis stocks were up sharply on Tuesday on a report by the Associated Press that the U.S. Drug Enforcement Administration is poised to reclassify marijuana. This news has sparked optimism among investors in the cannabis industry, who see the potential for increased demand and profitability as federal restrictions on marijuana are loosened. The move could also lead to greater acceptance of marijuana as a legitimate form of medicine and reduce the stigma associated with the drug.
(CNN) — The Biden administration will move Tuesday to reclassify marijuana as a lower-risk substance, a person familiar with the plans told. This decision could have far-reaching implications for the cannabis industry and patients who rely on the drug for medical purposes. It could also signal a shift in federal policy on marijuana and pave the way for broader legalization efforts at the federal level.
The DEA is reportedly moving to reclassify marijuana as a less dangerous drug in a monumental decision. This decision could have significant implications for how marijuana is regulated and could lead to increased access to the drug for patients who could benefit from its therapeutic properties. It could also create new opportunities for businesses in the cannabis industry and generate tax revenue for states that choose to legalize marijuana.
In a major shift, marijuana could be reclassified as a less dangerous drug in the U.S., according to reports. Does that mean it's one step closer to federal legalization? The move could have far-reaching implications for patients who rely on marijuana for medical purposes and for the cannabis industry as a whole. It could also lead to increased research into the drug's potential therapeutic uses and pave the way for the development of new treatments for a variety of conditions.
